Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical Therapeutics|January 6, 2016
Lurasidone Dose Response in Bipolar Depression: A Population Dose-response AnalysisSunny Chapel, Yu-Yuan Chiu, Jay Hsu, et al.Human Psychopharmacology|September 10, 2013
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesSheldon Preskorn, Larry Ereshefsky, Yu-Yuan Chiu, et al.British Journal of Clinical Pharmacology|February 28, 2007
Pharmacokinetics of a novel agent, R667, in patients with emphysemaYu-Yuan Chiu, Michael D Roth, Stanley Kolis, et al.Drug Metabolism and Drug Interactions|May 15, 2014
Lurasidone drug-drug interaction studies: a comprehensive reviewYu-Yuan Chiu, Larry Ereshefsky, Sheldon H Preskorn, et al.Pharmacotherapy|November 28, 2006
Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administrationAndrea L True, Yu-Yuan Chiu, Ralph A Demasi, et al.Clinical Therapeutics|December 4, 2015
Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric DisordersRobert L Findling, Robert Goldman, Yu-Yuan Chiu, et al.Clinical and Translational Science|March 2, 2021
Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's diseaseFelix Agbo, Ryan L Crass, Yu-Yuan Chiu, et al.Pharmaceutical Research|May 20, 2003
Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cellsYu-Yuan Chiu, Kazutaka Higaki, Brien L Neudeck, et al.Neurology and Therapy|May 15, 2021
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label StudyFelix Agbo, Stuart H Isaacson, Ramon Gil, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 20, 2007
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney functionPablo Tebas, Nicholas Bellos, Christopher Lucasti, et al.Pageof 2